There is a well-established link between the severity of hypertriglyceridaemia and acute pancreatitis and long-term triglyceride-lowering therapies known to prevent episodes of acute pancreatitis. The...

Aims/hypothesis The pathogenesis of hypertriglyceridaemia is explained by a complex interplay between genetic and environmental factors. We hypothesised that intrahepatic lipid (IHL) content, which dr...

There is a well-established link between the severity of hypertriglyceridaemia and acute pancreatitis and long-term triglyceride-lowering therapies known to prevent episodes of acute pancreatitis. The...

Nature Reviews Cardiology, Published online: 24 March 2026; doi:10.1038/s41569-026-01281-zApolipoprotein C-III (apoC-III) inhibition represents a major therapeutic advance in the management of severe hypertriglyceridaemia and pancreatitis. The potential role of apoC-III inhibition in preventing atherosclerotic cardiovascular disease will depend on rigorous outcomes data, appropriate patient selection and equitable implementation across healthcare systems. Beyond the lowering of triglyceride levels, meaningful clinical benefits and broad accessibility will determine the long-term success of this therapeutic approach.

Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.

There is a well-established link between the severity of hypertriglyceridaemia and acute pancreatitis and long-term triglyceride-lowering therapies known to prevent episodes of acute pancreatitis. The...

Ionis' Tryngolza has been approved for severe hypertriglyceridaemia, opening the door to what the company thinks could be a $3bn market opportunity.

Hypertriglyceridaemia is an important risk factor for cardiovascular morbidity and mortality. With a prevalence of >10% in the adult population, hypertriglyc

Up-to-date medical news aggregated from trusted medical associations, journals, physicians and news outlets from around the world.

The drug was recently approved in the US for familial chylomicronaemia syndrome

Hypertriglyceridaemia (HTG) is an independent risk factor for small fibre neuropathy in patients with type 1, type 2 diabetes, and obesity. This study assessed for evidence of small nerve fibre damage and cardiac autonomic dysfunction in in...

Hypertriglyceridaemia (HTG) is an independent risk factor for small fibre neuropathy in patients with type 1, type 2 diabetes, and obesity. This study assessed for evidence of small nerve fibre damage and cardiac autonomic dysfunction in in...

Hyperuricaemia was positively associated with dyslipidaemia and hypertriglyceridaemia. SUA mediated the effect of insulin resistance on triglyceride metabolism in patients with T2DM. A potential benef...

Hypertriglyceridaemia is a common clinical condition. Triglycerides (TGs) have long been recognised as a risk factor for atherosclerotic cardiovascular disease (ASCVD). Genetics, epidemiological studi...